Orthopedics Business Separation — Carve-Out & Stranded Cost Elimination
JNJ has announced the planned separation of its orthopedics business, a multi-billion dollar segment. CFO Joe Wolk explicitly stated they will 'take this opportunity to look and see where there's areas of opportunity efficiency to eliminate stranded cost' mirroring the Kenvue consumer health separation. This requires massive IT carve-out, finance/HR separation, supply chain de-coupling, TSA design, and Day 1/Day 2 readiness work. Tim Schmid confirmed the separation 'enables greater capital allocation to vision, supporting both R&D, commercial execution, and digital transformation,' signaling that JNJ views this as a portfolio transformation catalyst, not just a divestiture. The ortho business represents approximately $8.8B+ of medtech revenue context and 30%+ of medtech assets currently in lower-growth markets.
CFO Joe Wolk explicitly discussed stranded cost elimination and referenced the consumer health separation playbook. Tim Schmid confirmed ortho separation enables capital reallocation. CEO Joaquin Duato positioned the separation as a strategic portfolio shift. Multiple executives corroborated across prepared remarks and Q&A.
JNJ has prior experience with Kenvue separation where they used external advisors extensively. Business separations of this scale require Big 4 / Accenture-class firms for IT carve-out, TSA design, and standalone readiness. JNJ is known to engage external advisors for major transactions. Slight deduction because incumbents from Kenvue separation may have advantage.
This is a transformational multi-year program that reshapes JNJ's entire MedTech segment. Post-separation, 70%+ of MedTech assets will be in high-growth markets vs. ~50% today. The separation touches every function: IT, finance, HR, supply chain, legal, regulatory. This is a board-level strategic initiative.
Joe Wolk stated stranded cost work needs to be 'in place for 2027' but they'll 'get a jump start on that in 2026.' This implies active planning and execution in 2026 with a hard deadline. Separation programs typically run 18-24 months. Engagement window is now.
While no specific separation budget was disclosed, the Kenvue separation cost hundreds of millions in total separation-related charges. CFO explicitly referenced stranded cost elimination as a 2026-2027 priority. The ortho business scale (~$8B+ revenue) implies a separation budget in the hundreds of millions.
Business separation/carve-out advisory is a core Big 4 and Accenture capability. This involves IT separation (ERP carve-out, data migration), finance transformation (standalone reporting, treasury), HR transformation (benefits, payroll), supply chain separation, and TSA negotiation. Perfect fit for professional services.
Based on Kenvue separation precedent and JNJ's $94B+ revenue scale, the total advisory spend across all workstreams (IT carve-out, finance, HR, supply chain, legal, Day 1 readiness) could exceed $50M across multiple firms. Individual firm engagements likely $20M-$50M for primary advisor roles.
Joe Wolk
Budget Holder
Joaquin Duato
Decision Maker
Tim Schmid
Champion
Darren Snellgrove
Influencer
CFO confirmed stranded cost elimination must be 'in place for 2027' with a 'jump start in 2026.' Separation planning is actively underway. Advisory selection for major workstreams (IT carve-out, finance separation, standalone readiness) is likely happening in H1 2026. Missing this window means missing the primary engagement.
Joe Wolk stated: 'with the orthopedic separation, much like we did with the consumer health separation, we're gonna take this opportunity to look and see where there's areas of opportunity efficiency to eliminate stranded cost.' Tim Schmid confirmed: 'the ortho separation enables greater capital allocation to vision, supporting both R&D, commercial execution, and digital transformation.' The Kenvue (consumer health) separation in 2023 involved extensive use of external advisors for IT carve-out, standalone finance/HR, and TSA design. JNJ will replicate this playbook. Ortho represents ~30% of MedTech assets in lower-growth markets, and separation will shift MedTech portfolio to 70%+ high-growth.
$20M - $50M
Data sources the agent used to generate this lead
Sector: Healthcare | Industry: Drug Manufacturers-General | Employees: 0 | Price: $235.37 Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease...
**Operator:** Good morning, and welcome to Johnson & Johnson's Fourth Quarter 2025 Earnings Conference Call. All participants will be in a listen-only mode until the question and answer session of the conference. This call is being recorded. If anyone has any objections, you may disconnect at this time. If you experience technical difficulties during the conference, you may press 0 to reach the operator. I will now turn the conference call over to Johnson & Johnson. You may begin. **Darren Snel...
Get notified when new leads drop for $JNJ
Free AI-generated enterprise leads from financial filings.